ãã€ãªãã¯ãããžãŒå ¬è¡šãããæŽå¯
ã¯ã¯ãã³ã®çްèå¹é€åªäœã¯ã现èãµã€ã¯ã«ã調ç¯ããã®ã§ãé«åºŠãªå»çã«ãããŠå€§ããªåœ¹å²ãæãããŠããŸãã 埮çç©ã现èããŸãã¯å°ããæ€ç©ã®æé·ãæ¯ããããã«éçºãããæ¶²äœãã²ã«ã®åœ¢æ ã§å©çšã§ããæé·åªäœã§ããã¯ã¯ãã³åžå ŽèŠæš¡ã®ã°ããŒãã«çްèå¹é€åªäœã¯US$ã§è©äŸ¡ 1,235.5å 2018幎1æ1æ¥ãäºå ±æé(å¹³æ30幎1æ1æ¥ïœå¹³æ30幎2æ30æ¥)ã«ãCAGRã®å±ç€ºãäºå®ãããŠããŸãããããã£ãŒã« 1. ã¯ã¯ãã³åžå ŽäŸ¡å€(US $ Mn)ã®ã°ããŒãã«ã»ã«æåã¡ãã£ã¢ãå°åå¥ã2018åºå ž:ã³ããŒã¬ã³ãããŒã±ããã€ã³ãµã€ãåæ(2019)ã¯ã¯ãã³åžå Žã«ãããã°ããŒãã«çްèå¹é€åªäœã®æ®åãæåŸ ãã... ãã£ãšèŠã
Ubiquitiné µçŽ åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ãŠãããã³é µçŽ åžå ŽèŠæš¡ã¯ã2026幎ãã2033幎ãŸã§ã®USD 4.8åã§è©äŸ¡ããããšæšå®ããã2033幎ãŸã§ã«USD 12.3åã«éãããšäºæ³ãããããããã£ãŒã«ubiquitinã®é µçŽ ã®åžå Žã¯èçœè³ªã®äœäžããã³çްèããã»ã¹ã調ç¯ããããã«å¿ é ãããã¯ãã®ç¯å²ããæã£ãŠããŸãã äž»èŠãªãããã¯ãéšéã¯E1掻ååã®é µçŽ ãE2ã®conjugatingãå«ãã§ããŸã é µçŽ , ãš E3 ã®ãªã¬ãŒ, ããããã¯ãubiquitination ã«ã¹ã±ãŒãã§éèŠãªåœ¹å²ãæãããŠããŸã. ãããã®é µçŽ ã¯è¬å€ã®çºèŠã§åºãå©çšãããŠããŸã... ãã£ãšèŠã
ã©ã€ããµã€ãšã³ã¹åžå Žã補åã¿ã€ãå¥ïŒå»è¬åããã€ãªå»è¬åãå»çæ©åšã蚺æè£œåãæ é€è£å©é£åãå®éšåšå ·ããã³æ¶èåããã®ä»ïŒç ç©¶ååŠåïŒïŒãã¢ããªã±ãŒã·ã§ã³å¥ïŒåµè¬ãã²ããã¯ã¹ãããããªãã¯ã¹ã现èçç©åŠã埮çç©åŠãããã³åå蚺æïŒããšã³ããŠãŒã¶ãŒå¥ïŒåŠè¡ç ç©¶æ©é¢ã補è¬äŒæ¥ããã³ãã€ãªãã¯ãããžãŒäŒæ¥ãç é¢ããã³èšºæã»ã³ã¿ãŒãåèšç ç©¶ïŒ çµç¹ (CRO)ãããã³æ¿åºæ©é¢)ããã¯ãããžãŒå¥ (ã²ãã ã·ãŒã¯ãšã³ã·ã³ã°ãCRISPR ãã¯ãããžãŒã質éåææ³ãé¡åŸ®é¡æ³ããããŒãµã€ãã¡ããªãŒãããã³ããªã¡ã©ãŒãŒé£éåå¿ (PCR))ãæ²»çåéå¥ (è «çåŠãå¿èè¡ç®¡åŠãç¥çµåŠãææçãå ç«åŠãåžå°çŸæ£)ã... ãã£ãšèŠã
ã¢ããã¯ã¬ãªã·ã¹ã¯ãã¢ãã©ã«ãŸãã¯ãã¹ç ãšãåŒã°ããEpstein-BarrãŠã€ã«ã¹ã«ããæææ§çŸæ£ã§ãã ãã®ãŠã€ã«ã¹ã¯ãäžè¬çã«ãã¹ç ãšããŠåŒã°ããåŸæ¶²ã®çã¿ãéããŠäžè¬ã«åºãããŸãã ãŸããããªã³ã¯ãéå ·ã®å ±æãªã©ãä»ã®æ¹æ³ã§æ®åããããšãã§ããŸãããããã«ãã¹ãŠã€ã«ã¹4ãšãåŒã°ããEpstein-BarrãŠã€ã«ã¹ã¯ãã¢ãã»ãã¹ç ã®åå ç©è³ªã§ãã Epstein-BarrãŠã€ã«ã¹ã¯ãããã«ãããæãäžè¬çãªçš®é¡ã®ãŠã€ã«ã¹ã§ããããã«ãã¹å®¶æã«ããã8ã€ã®æ¢ç¥ã®ãããã«ãã¹ãŠã€ã«ã¹ã¿ã€ãã®äžã€ã§ãã 2018幎ã«ãã¬ããã»ãããã³ãœã³ã»ããç ç©¶æãå ¬è¡šããããŒã¿ã«ãããšããšãã¹ã¿ã€ã³ã»ããŒ... ãã£ãšèŠã
å ç«ã¬ããŒããªãŒ ã·ãŒã±ã³ã¹åžå Ž - æŽå¯å ç«ã¬ããŒããªãŒã·ãŒã±ã³ã·ã³ã°ã¯ããã€ãªããŒã«ãŒãã£ã¹ã«ããªãŒã§åºã䜿çšãããåççãªå»è¬åéçºã®æåçãšè²»çšå¹æãåäžããŸãã ããšãã°ã2017幎11æãããå ç«çæ³(C3i)ã®åçšåã»ã³ã¿ãŒã§ã¯ãã«ããã®ãã€ãªããŒã«ãŒããã³èšºæãŠãããã§T现èå容äœããŒã¿ã·ãŒã±ã³ã·ã³ã°ãµãŒãã¹ãæäŸããŠããŸãã ããŒãœãã©ã€ãºãå»è¬åã®éèŠã®å¢å , é çªã«, å ç«ã¬ããŒããªãŒ ã·ãŒã±ã³ã¹åžå Žæé·ãæ¯æŽããããšãæåŸ ãããŸã, ããŒãœãã©ã€ãºãå»è¬åã¯ã蚺æã«é¢ããŠè¡ãããæ±ºå®ãå°ãããã«ãåã ã®éºäŒåãããã¡ã€ã«ã䜿çšããŸã, äºé², çŸæ£ã®æ²»ç.äžççãªå ç«ã®... ãã£ãšèŠã
æŸå°ç¶é éšã®èšæ£ã¯åžå ŽèŠæš¡ããã³äºæž¬â 2026 â 2033 ãæ€ããŸãäžççãªæŸå°ç¶é éšã®åé€ã®ã€ã³ãã©ã³ãã®åžå ŽèŠæš¡ã¯2026幎ã®USD 525,000,000ã§è©äŸ¡ããã2033幎ãŸã§ã®USD 835,000,000ã«éãããšäºæ³ãããŸãã2026幎ãã2033幎ãŸã§ã®6.1%ã®æ··åç©ã®å¹Žæ¬¡æé·ç(CAGR)ãå±ç€ºããŸãããããã£ãŒã«æŸå°ç¶é éšã®Resectionã®ã€ã³ãã©ã³ãã®åžå Žã¯ç¯å²ãæäŸããŸã æŽåœ¢å€ç§è£ 眮 èã®æŸå°ç¶ã®é éšãåãæ¿ãããããŸãã¯æ¯æããããã«èšèšãããŠããŠã骚æã倿§æ¡ä»¶ã«ãã£ãŠäžè¬ã«åœ±é¿ãããã ãããã¯ãã¯å¥ã®å¿è匷ãanatomiesã®ããã«åããããã... ãã£ãšèŠã
ãã£ãã·ã¥ã®ç§»æ€ 補åããã³ãµãŒãã¹åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033äžççãªçµç¹ã®ç§»æ€è£œåããã³ãµãŒãã¹åžå Žã¯ã2026幎ãã2033幎ãŸã§ã®USD 9.7åã§è©äŸ¡ãããUSD 17.3åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ãã®åžå Žã¯ã骚ãç®èãè§èãè»éªšãè ±ãããã³å¿èåŒãå«ãæå·ããããçµç¹ã修埩ã亀æããŸãã¯åçããããã«äœ¿çšããã補åãšèšåºãµãŒãã¹ãç¶²çŸ ããŠããŸãã åžå Žã¯ãæŽåœ¢å€ç§ãå¿èè¡ç®¡ãçŒç§ãããã³å建æè¡ãªã©ã®å»ççšéã®åºãç¯å²ããµããŒãããŠããŸãã æé·ã¯ãå€å·ãæ ¢æ§çŸæ£ãããã³å¹Žéœ¢é¢é£ã®å€æ§æ¡ä»¶ã®äžæã®çºççã«ãã£ãŠé転ãããäžçã®å€ç§çåŠçœ®ãé«ããŸãã çµ... ãã£ãšèŠã
Psoriasisã¯ç°åžžãªç®ã®ãããã«ãã£ãŠç¹åŸŽä»ããããécommunicableèªå·±å ç«çŸæ£ã§ãã ãããã®ç®èã®æç¹ã¯èµ€ããããã¿ããããŠã¹ã«ãªãŒã§ãå°ããã屿çã«ããããå šèº«ãèŠããŸãã ç®èã®æªæã¯ããã®å Žã§ä¹Ÿæ§ç®èã®å€åãåŒãèµ·ããå¯èœæ§ããããŸãã, KoebnerçŸè±¡ãšåŒã°ããçŸè±¡.也ç¬ã¯ãéåžžããã©ãŒã¯ãã¬ãããéããã©ãŒã«ãããã³ãšãªã¹ããããã¯ã®5ã€ã®äž»èŠãªã¿ã€ãããããŸãã ããªãºã 也ç¬ãå¥å也ç¬ã¯ãå ±åãããçäŸã®ããã90%ãå ãã也ç¬ã®æãæµè¡ã®ã¿ã€ãã§ãã 身äœã®æãäžè¬çã«åœ±é¿ãåããé åã¯ãæµããããŠé ç®ã®åšãã®æµãèŒãã®åŸããå«ã¿ãŸãã ã°ããã¡ã€ãã®ä¹Ÿ... ãã£ãšèŠã
æ€ç©å¹¹çްèåžå ŽæŠèŠæ€ç©å¹¹çްèã¯æ€ç©ã®è¡šç®å ã®æªå现èã§ãã æ€ç©å¹¹çްèã¯ãæ€ç©ã®æŽ»åã®èµ·æºãšããŠæ©èœããæ€ç©ã®ããŸããŸãªçµç¹ãèåšã圢æããåé§çްèã®å®å®ããäŸçµŠãæäŸããŸãã æ€ç©å¹¹çްèã¯ã2ã€ã®ç¹åŸŽçãªç¹æ§ã«ãã£ãŠç¹åŸŽä»ããããŸãå¥ã®çްèã¿ã€ããäœæãã幹现èã®æ°ãå®å®ããŠããããã«èªå·±æŽæ°ããã æ€ç©å¹¹çްèåžå Žã¯ãæ€ç©çްèã®ãã®èœåã«çŠç¹ãåœãŠããããã£ãŠãèœãæ ¹ããã³èœããã®å å·¥æœåºç©ã¯é«éèŠã«ããã屿çšéã«åºã䜿çšãããŠããŸããæè¡ã®é²æ©ã¯ãæ€ç©å¹¹çްèã«ãã£ãŠéçºãããåçãããæ€ç©ããå¹é€äžã®åäžã»ã«ã«ãã£ãŠäœæãããäºæ¬¡ä»£è¬ç©ã®ããããã䜿çšããããšã«ã€ãªãããŸããã ãããã¯... ãã£ãšèŠã
ç®äžãã€ãªããžã«ã«åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 20332026幎ãã2033幎ã«ãããŠãäžçç®äžãã€ãªããžã«ã«åžå ŽèŠæš¡ã¯44.8åç±³ãã«ã«çžåœããèŠèŸŒã¿ã§ã2033幎ãŸã§ã«78.9åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ãã®åžå Žã¯äžæã®åªå é äœã«ãã£ãŠé転ãããå®å®ããæé·ãçµéšããŸã æ ¢æ§çŸæ£ãèªå·±ç®¡ççæ³ã®æ¡çšã®å¢å ããã³æ¹åãããå¿è匷ã䟿å©ã®ããã®éèããã®subcutaneousé éãžã®ã·ããã äž»èŠãªæ²»çåºåã¯è «çåŠãå«ãã§ããŸãã èªå·±å ç«é害ãããã³ãŸããªç æ°ãçç©ç補å€ãã¿ãŒã²ããã«ãããåŠçœ®ã®éžæãæäŸããã ãã¬ãã£ã«ãã·ãªã³ãžããªãŒãã€ã³ãžã§ã¯ã¿ãŒãªã©ã®åŠæ¹ãã... ãã£ãšèŠã
äžæ¢ç¥çµç³»(CNS)çŸæ£ã¯ãè³ãæ£åžžãªæ©èœãå€±ãæ¡ä»¶ã®å€æ§ãªã°ã«ãŒããå«ã¿ãããã«ãã£ãŠæ¥ã ã®ç掻掻åã«æ¥ã åäœããèœåãæžããã ãããã¯ãéºäŒãªã©ã®ããã€ãã®çç±ã§èµ·ããããšãã§ããŸãã, ä»ã®äººã¯æªæã«ãã£ãŠåŒãèµ·ããããŸãã, ããã€ãã¯ãææã«ãã£ãŠåŒãèµ·ãããã. CNSçŸæ£ã®æ²»çãæäŸããæãå°é£ã¯ãååãªéã®è¡è³ããªã¢(BBB)ã®æµžéãå¯èœã«ããŸãã ããã€ãã®ã»ã«ãšéºäŒåæ²»ç(CGT)ã¯ãèæ€çèçž®(SMA)ãããŒãã³ãœã³ç ãã¢ã«ããã€ããŒç (AD)ãå€çºæ§éªšç²é¬ç(MS)ãå«ããæãç Žå£çãªCNSéå®³ãæšçããããã®èšåºéçºã®ããŸããŸãªæ®µéã«ããã ãã³ãã£ã³ãã³ç (HD... ãã£ãšèŠã
è¶³å Žã¯ãå»ççšéã®ããã®æ°ããæ©èœçµç¹ã®åœ¢æã®ããã®æãŸããæ¹æ³ã§ã现èãçµç¹ã®æé·ãåºæ¿ããããã«äœ¿çšãããææã§ãã ãããã®è¶³å Žã¯ãæªæãç æ°ãå·ã€ããŠããèåšãèåšç³»ã®ãµããŒããšããŠäœ¿çšã§ããŸãã åçå»çããã³çµç¹å·¥åŠã¯ãç¹å®ã®æå·ããèåšãŸãã¯èåšç³»ã«é©ããè¶³å Žã圢æããããã«äœ¿çšããããšãã§ããŸãã çµç¹å·¥åŠã¯ã现èã®çµåãé©ããçååŠçããã³physiochemicalèŠå ããã³ç¶æãå埩ãããããŸãã¯çç©çµç¹ãæ¹åããããã«æŽç·Žãããå·¥åŠæ¹æ³ãææããçç©å»åŠå·¥åŠã®éšåã§ãã è¶³å Žã¯ãäœå ã§å¹é€ããããããŸãã¯æªæã®éšäœã«çŽæ¥æ³šå ¥ããŠçµç¹ãåæããæ²»çãä¿é²ããããšãã§ããŸã... ãã£ãšèŠã
ãªã³ãè «ã¯ãTãªã³ãçããã³Bãªã³ãçã«çްèã®çš®é¡ã«åºã¥ããŠãããã«2ã€ã®ã«ããŽãªã«åãããããªã³ãçã«åœ±é¿ãäžããã¿ã€ãã®çã§ãã Angioimmunoblastic(ã¢ãã®ã ã ) T现èãªã³ãè «(AITL)ã¯ããªã³ãç³»Tãªã³ãçã«äœçšããéããžãã³ãªã³ãè «ã®ãŸããªåœ¢æ ã§ãã ç¹å®ã®ãªã³ãç¯é åã®æ¡å€§ã«ã€ãªããTãªã³ãçã®å€åœ¢ã«ãã£ãŠAITLãç¹åŸŽä»ããããŸãã ç æ°ã¯å ç«ã·ã¹ãã ã®æ©èœäžå šã«ã€ãªãããæç¶çãªç±ãçºç¹ãäœéæžå°ãçµç¹ã®è «ããªã©ã®çç¶ãåŒãèµ·ãããŸãã AITLã«èŠããå人ã®ããã®äž»èŠãªæ²»çã«ã¯ãã³ã«ãã³ã¹ããã€ããåå€ååŠçæ³ãããã³ãã«ããšãŒãžã§ã³ãååŠçæ³ãå«ãŸããŸã... ãã£ãšèŠã
ãã€ãªããžãã¯ã¯ãç¹ã«æŽåœ¢å€ç§ã§èšåºç ç©¶ã§äœ¿çšãããææ°ã®æ²»çæ³ã§ãã èæ€ã®çæ åŠã¯æé·ããã³å·®å¥ãä¿é²ããæŽ»åçãªçްèããã»ã¹ã«ãã£ãŠåšå²ãå€ããçç©ææã§ãããããã«ãã£ãŠå·å®³ãŸãã¯æ¡ä»¶ã®ä¿®çãããŠå埩ã§å©ããŸãã äžéšã®çæ åŠã¯ã人ã®èªç¶ãªéªšç§»æ€ã®ä»£æ¿ãšããŠäœ¿çšãããããã«èšèšãããŠããããä»ã®çæ åŠã¯ãã«ãã£ã©ã®ãã¹ãšãããŒæ§é ã®ä¿®åŸ©ãšåçãä¿é²ããããçŸåšéçºæ®µéã«ãããã°ããŒãã« Spine Biologics åžå Ž â ãã€ããã¯ã¹æè¿ã®è£œåçºå£²ã¯ãäžççãªèæ€ãã€ãªããžã«ã«åžå Žæé·ãåŸæŒãããèŠèŸŒã¿ã§ãã äŸãã°ã2020幎1æ9æ¥ããã€ã€ã«ã»ãã€ãªããžã¹ãã£ãã¯ã¹ãçæãã... ãã£ãšèŠã
ã³ã³ãããŒã·ã§ã³ã¯ã¯ãã³ã¯ã2ã€ä»¥äžã®ã¯ã¯ãã³ã1ã€ã®ã¯ã¯ãã³ã·ã§ããã«çµåãããŠãŒã¶ãŒã¯æ°åã®ç æ°ã®ããã«ããã€ãã®ã·ã§ããããååŸã§ããŸããã ããšãã°ãMMRã¯ã¯ãã³ã¯3ã€ã®ç æ°ã®ãŠã€ã«ã¹ã«å¯Ÿããä¿è·ãæäŸããŸãã ãŸããMMRVã¯ã¯ãã³ã¯ãMMRã¯ã¯ãã³ãšããã³ããã¯ã¹ã¯ã¯ãã³ãçµã¿åãããŠããŸãã çµã¿åããã¯ã¯ãã³ã®å©ç¹ã¯ãçã¿ãäžå¿«æãã¿ã€ã ãªãŒãªäºé²æ¥çš®ã管çã³ã¹ããåæžããå ç«ã»ã³ã¿ãŒãžã®å°æ°ã®èšªåã䌎ãããå°ãªãæéãå«ã¿ãŸãã ãŸããã³ã³ãããŒã·ã§ã³ã¯ã¯ãã³ã¯ãç¹å®ã®ã¯ã¯ãã³ã«æšå¥šãããæå°éã®ééãç¶æãããŠããããšãæäŸããåäžã®æåã¯ã¯ãã³ãšçµã¿åããã¯ã¯ãã³ã®éã§... ãã£ãšèŠã
ããåžå ŽèŠæš¡ãšäºæž¬ã®ããã®ããŒãœãã©ã€ãºãããéºäŒåæ²»ç - 2026 - 2033ããåžå ŽèŠæš¡ã®äžççãªããŒãœãã©ã€ãºãããéºäŒåæ²»çã¯ã2026幎ãã2033幎ãŸã§ã®USD 9.8åã§è©äŸ¡ããã15.4%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã瀺ã2033幎ãŸã§ã®USD 27.5åã«éãããšäºæ³ãããŸãããããã£ãŒã«ããã«å¯ŸããããŒãœãã©ã€ãºãããéºäŒåæ²»çã¯ãåã ã®éºäŒåè «çãããã¡ã€ã«ã«åãããæ²»çãœãªã¥ãŒã·ã§ã³ãé«åºŠåããŠããŸãã ãããã®è£œåã¯ããŠã€ã«ã¹ãã¯ã¿ãŒãCRISPRããŒã¹ã®ã·ã¹ãã ããŸãã¯åæDNA/RNAæ§é ãªã©ã®éºäŒåå·¥åŠæè¡ã䜿çšããŠãããã®é²è¡ãä¿ãéºäŒåç°åžžãä¿®æ£ãŸã... ãã£ãšèŠã
Bispecificæäœåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«ãã€ã¢ã«æäœåžå ŽèŠæš¡ã¯ã 2025幎ã®USD 4.2åã§è©äŸ¡ãããUSD 12.7ã«éããèŠèŸŒã¿ 2032幎(æå20幎)10幎(æå40幎)10æ è€å墿®ç(CAGR) 2025幎ãã2032幎ã«ãããŠ16.4%ããããã£ãŒã«ãã€ã¹ãã¯ãã£ã æäœãããã¯ãã¯2ã€ãçµåããããã«èšèšãããé«åºŠã®çç©çæ²»çè¬ã§ã åæã«ç°ãªã£ãæåã ãããã®è¬ã¯ãªãã€ã¬ã¯ãããããã«èšèšãããŠããŸã ç æ°ã®ã¿ãŒã²ãããç¹ã«è «çåŠããã³ ãªãŒããã¥ãŒã³é害ã Bispecificæäœã¯å ç«ã®æŽ»çºåãé«ããæ¹åã§ããŸã 粟å¯ãã¿ãŒã²... ãã£ãšèŠã
ç人工æç²Ÿåžå Žã補åã¿ã€ãå¥ïŒç²Ÿæ¶²ïŒåŸæ¥åç²Ÿæ¶²ãæ§å¥ç²Ÿæ¶²ïŒãæ©åšããã³æ¶èåïŒäººå·¥æç²Ÿã¬ã³ããã³ã·ãŒã¹ã粟液ã¹ãããŒ/ã¯ã©ã€ãªãã€ã¢ã«ã粟液ä¿åããã³è§£åæ©åšïŒã¿ã³ã¯ããŠã©ãŒããŒïŒãåŠå𠿀åºããããããã³ãã®ä»ã®æ©åšïŒé²è·æãæ€é¡ïŒïŒãåç©ã¿ã€ãå¥ïŒä¹³çããã³çèïŒ çïŒããµãŒãã¹ã®çš®é¡å¥ïŒäººå·¥æç²ŸãµãŒãã¹ïŒæåž«/ç£å»åž«ã宿œïŒãåŠåš 蚺æãµãŒãã¹ãéºäŒã³ã³ãµã«ãã£ã³ã°ããã³éžæãµãŒãã¹ãä¿ç®¡ããã³æµéãµãŒãã¹ïŒãæµéãã£ãã«å¥ïŒãªã³ã©ã€ã³ããã³ãªãã©ã€ã³ïŒãæææš©å¥ïŒå ¬çããã³æ°éïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãããã³ã¢ããªã«ïŒ... ãã£ãšèŠã